Clinical Translation

From Circuit Insights
to Clinical Outcomes

Direct access to a comprehensive epilepsy surgery program is what separates our lab from most computational neuroscience groups. Our research runs in both directions: clinical care generates scientific questions, and basic discoveries return to the bedside.

Our Competitive Advantage
Clinical Access Most BCI Labs Don't Have
Many BCI and computational neuroscience labs work with archived datasets. At WVU, our stereoEEG cases are ongoing, our patients are in the room, and our research protocols run live in the epilepsy monitoring unit. This continuity between clinical care and investigation is not easily replicated.
50+
SEEG research participants enrolled
200+
Epilepsy monitoring unit admissions per year
8+
Active implantable neuromodulation devices managed
3
IRB-approved intracranial research protocols
Clinical Research Programs

Four Translational Pillars

Each program connects a scientific question directly to patients we are actively treating at WVU Medicine.

Program 01
Epilepsy Surgery Program
WVU operates a full-spectrum epilepsy surgery program including resective surgery, laser ablation (LITT), and the complete stereoEEG (SEEG) implantation pathway. Our lab has an IRB-approved research protocol that runs in parallel with standard clinical SEEG, enabling us to record high-density intracranial LFP from temporal, frontal, limbic, and parietal structures while patients undergo presurgical evaluation.
Patients give written informed consent to share their intracranial recordings, behavioral data, and clinical outcomes for research. This makes our dataset one of the richest platforms in the mid-Atlantic region for human single-structure electrophysiology.
StereoEEG (SEEG) Resective surgery LITT ablation Phase II-III presurgical evaluation 50+ enrolled
Program 02
Surgical Neuromodulation
Our clinic manages one of the larger implantable neuromodulation programs in the region, including Deep Brain Stimulation (DBS), Responsive Neurostimulation (RNS), and Vagus Nerve Stimulation (VNS). This patient population provides a unique window into the real-world effects of circuit-level neuromodulation.
Long-term device programming data, stimulation-triggered artifact analysis, and stimulation-related mood and cognitive changes are all tractable questions in this cohort. We collaborate closely with Dr. Phillip Konrad's neurosurgical program at WVU.
DBS (ANT, GPi, STN) RNS system VNS Closed-loop data extraction Programming optimization
Program 03
Depression Biomarkers in Epilepsy
Depression affects up to 50% of patients with drug-resistant epilepsy and is the strongest predictor of quality of life impairment. Despite its clinical significance, depression in epilepsy is systematically understudied and underdiagnosed. Our K23-funded research directly addresses this gap.
We are characterizing a frontal-limbic circuit-specific subtype of depression in epilepsy using intracranial EEG biomarkers acquired during standard SEEG evaluations. Candidates include frontal-limbic beta coherence, theta power in the subgenual cingulate, and phase-amplitude coupling within the amygdala-prefrontal cortex axis. This work is mentored by Dr. Helen Mayberg (ISMMS) and Dr. Muhammad Parvaz (WVU).
K23 NIMH funded Frontal-limbic beta Subgenual cingulate PHQ-9 / NDDI-E Circuit biomarkers
Program 04
Precision Medicine in Epilepsy
Epilepsy is not one disease. Seizure semiology, genetic architecture, structural substrate, and comorbidity burden vary enormously between patients. Our goal is to use high-dimensional intracranial and behavioral phenotyping to identify patient subtypes that predict differential responses to antiseizure medications, surgical approaches, and neuromodulation strategies.
This program is directly relevant to the Appalachian patient population we serve, where healthcare access barriers, economic disadvantage, and high rates of psychiatric comorbidity compound the complexity of epilepsy management. We are developing a SENTINEL-funded care coordination model for patients with comorbid epilepsy and sleep disorders in rural WV.
Phenotypic clustering Genetic epilepsy Biomarker-guided therapy SENTINEL RAG grant Rural health equity
Serving Appalachia: Why Location Is a Strength
West Virginia has some of the highest rates of epilepsy in the United States, driven by elevated rates of traumatic brain injury, substance use disorder, genetic risk, and limited access to subspecialty care. WVU Medicine is the only Level 4 Epilepsy Center in the state. Our geographic position means we see the most complex, most underserved cases in the region. This is both a clinical responsibility and a scientific opportunity. It also means our findings are directly relevant to populations that academic medicine has historically overlooked.
Translational Model

How Clinical Care Drives Discovery

Our translational pipeline flows in both directions. Bedside observations generate scientific hypotheses. Laboratory findings return to improve patient care.

🏥
Bedside
Clinical SEEG, DBS, RNS, and VNS management generates intracranial recordings and longitudinal phenotypic data.
🔬
Bench
Signal processing, oscillatory biomarker extraction, machine learning classification, and circuit-level hypothesis testing.
🎯
Back to Bedside
Validated biomarkers inform DBS/RNS programming, surgical target selection, and psychiatric treatment decisions.
Special Program

Pediatric-to-Adult Transition Clinic

In collaboration with Dr. Peter Morton (Pediatric Neurology, WVU), we are developing a dedicated transition epilepsy clinic to address the well-documented care gap when patients with childhood-onset epilepsy age into adult care. The transition period is associated with increased mortality, medication non-adherence, loss to follow-up, and worsening psychosocial outcomes.

Get Involved

Clinical Research Opportunities

We actively recruit medical students, residents, and clinical research coordinators interested in bridging neuroscience and patient care in a comprehensive academic epilepsy center.

Join the Lab Our Research